Original news and analysis on international IP policy
Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. [Updated with response from UNFPA]
A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. [Updated]
Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T).
The problem of fake medicines is a big one. But precisely how big? The problem is, when reporting numbers, news stories, reports and institutions have historically bundled the different kinds of medicines together, says an expert at the WHO.
Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug.
A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions.
The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline.
A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases.
NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead?
For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV.
The global network of national influenza centres is at the core of the World Health Organization system of influenza surveillance and response. All year round those national influenza centres collect, interpret and share flu samples or genetic information with the WHO so that seasonal vaccines can be manufactured, and potential pandemics adequately identified and contained.
A new study by the World Health Organization finds that most countries will have the technological and the financial ability to reach universal health coverage in the next 13 years, according to authors.